Stock Market News
ReNeuron lands £1.5m grant to develop retinal disease treatment
Clinical stage stem cell business ReNeuron Group has won a £1.5m grant to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.
The grant, from innovation agency Innovate UK, will help to fund a collaborative programme between ReNeuron and its partners the Cell & Gene Therapy Catapult, Roslin Cell Therapies and University College London.
Sharon Grimster, Welsh General Manager at ReNeuron Group, said: "We and our collaborators are delighted to have won this latest grant from Innovate UK to develop a suite of robust and reliable release and characterisation assays reflecting the mechanism of action of our hRPC cell therapy candidate."
The hRPC cell therapy candidate is currently in the midst of phase I/II trials in the United States, studying the effects of the treatment on patients with genetic disorder retinitis pigmentosa.
The development of the treatment was earlier funded by Innovate UK, who supported the late pre-clinical development of the cell therapy candidate.
"This is a challenging but vital part of the broader commercial manufacturing strategy for the therapy and we are pleased to be working with leading academic and commercial manufacturing partners on this important programme of work," said Grimster.
As of 0822 BST, ReNeuron Group's shares were up 4.96% at 74.00p.
The grant, from innovation agency Innovate UK, will help to fund a collaborative programme between ReNeuron and its partners the Cell & Gene Therapy Catapult, Roslin Cell Therapies and University College London.
Sharon Grimster, Welsh General Manager at ReNeuron Group, said: "We and our collaborators are delighted to have won this latest grant from Innovate UK to develop a suite of robust and reliable release and characterisation assays reflecting the mechanism of action of our hRPC cell therapy candidate."
The hRPC cell therapy candidate is currently in the midst of phase I/II trials in the United States, studying the effects of the treatment on patients with genetic disorder retinitis pigmentosa.
The development of the treatment was earlier funded by Innovate UK, who supported the late pre-clinical development of the cell therapy candidate.
"This is a challenging but vital part of the broader commercial manufacturing strategy for the therapy and we are pleased to be working with leading academic and commercial manufacturing partners on this important programme of work," said Grimster.
As of 0822 BST, ReNeuron Group's shares were up 4.96% at 74.00p.
Related share prices |
---|
ReNeuron Group (RENE) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price